Related Experiment Videos
Clinical effectiveness of niludipine in patients with ischemic heart disease
Insights
Niludipine effectively treats ischemic heart disease by significantly reducing angina attacks and nitroglycerin use. This calcium channel blocker demonstrated high efficacy and excellent tolerability in patients with angina and hypertension.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) poses a significant health burden.
- Angina pectoris is a common symptom of IHD, impacting quality of life.
- Effective antianginal therapies are crucial for managing IHD.
Purpose of the Study:
- To evaluate the antianginal efficacy of niludipine, a novel calcium antagonist.
- To assess the impact of niludipine on angina attack frequency and nitroglycerin requirements.
- To determine the safety and tolerability of niludipine in patients with IHD.
Main Methods:
- A study involving 51 patients diagnosed with various forms of ischemic heart disease.
- Patients received niludipine at dosages ranging from 60 mg to 80 mg daily.
- Data collected included angina attack rates, nitroglycerin usage, blood pressure, and adverse events.
Main Results:
- Niludipine significantly reduced the mean weekly angina attack rate from 6.5 to 2.2 (p < 0.001).
- A significant decrease in nitroglycerin requirement was observed (p < 0.001).
- Complete control of angina was achieved in 71% of patients, with over 77% experiencing at least a 50% reduction in angina frequency. Niludipine showed 93.8% effectiveness in IHD patients and reduced blood pressure in hypertensive patients without side effects.
Conclusions:
- Niludipine is a highly effective antianginal agent for patients with ischemic heart disease.
- The drug demonstrates significant efficacy in reducing angina symptoms and medication needs.
- Niludipine is well-tolerated and shows potential for managing associated hypertension.
Abstract:
The antianginal efficacy of niludipine (Bay a 7167), a new calcium antagonistic drug, was investigated in 51 patients with ischemic heart disease. 16 patients were diagnosed as effort angina and 31 patients had both angina at rest and on effort. Six anginal patients had myocardial infarction. One patient was diagnosed as a variant form of angina and 3 others as unstable angina. 11 patients had essential hypertension. 49 completed the study and 2 dropped out. Niludipine (60 mg to 80 mg every 24 h) significantly reduced the mean weekly rate of angina attacks from 6.5 to 2.2 (p less than 0.001). Marked reductions of nitroglycerin requirement were also noted (p less than 0.001). In 71% of the patients complete control of anginal attacks was achieved, and in over 77% the frequency of angina was reduced by at least 50%. Niludipine was at 93.8% effective in patients with ischemic heart disease. It decreased significantly both systolic and diastolic blood pressure in angina patients with essential hypertension, but there were no significant changes of blood pressure in normotensive anginal patients. The agent was tolerated very well and there were no side effects. These findings suggest that niludipine is a highly effective drug for the treatment of both ischemic heart disease and essential hypertension.